Aug 8 |
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
|
Aug 7 |
Coherus BioSciences Q2 2024 Earnings Preview
|
Aug 1 |
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
|
Jul 2 |
Coherus out licenses Canadian rights to cancer drug Loqtorzi
|
Jun 28 |
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
|
Jun 27 |
Coherus to divest biosimilar against AbbVie’s Humira for $40M
|
Jun 27 |
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
|
Jun 5 |
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
|
May 31 |
Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
|
May 23 |
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|